Collegium Pharmaceutical, Inc.

NasdaqGS:COLL Rapport sur les actions

Capitalisation boursière : US$967.5m

Collegium Pharmaceutical Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Vikram Karnani

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDGn/a
Durée du mandat du directeur généralno data
Propriété du PDGn/a
Durée moyenne d'occupation des postes de direction4.3yrs
Durée moyenne du mandat des membres du conseil d'administration10.3yrs

Mises à jour récentes de la gestion

Recent updates

Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality

Nov 14
Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Oct 28
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Collegium Pharmaceutical: Diversifying And Growing

Aug 09

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Jul 24
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Jun 05
Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

May 13

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

May 10
It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24
These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05
There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12
Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Aug 09
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Mar 10
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Oct 18
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Jun 24
Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Collegium Pharmaceutical: Oversold And Cheap

Jun 12

PDG

Vikram Karnani (49 yo)

no data

Titularisation

Mr. Vikram Karnani is CEO, President & Director of Collegium Pharmaceutical, Inc. since November 12, 2024. Mr. Karnani was Executive Vice President and President, Global Commercial Operations and Medical A...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Michael Heffernan
Co-Founder & Chairman21.1yrsUS$330.61k0.087%
$ 840.7k
Colleen Tupper
Executive VP & CFO3.5yrsUS$2.73m0.061%
$ 591.3k
Shirley Kuhlmann
Executive VP6.7yrsUS$2.87m0%
$ 0
Scott Dreyer
Executive VP & Chief Commercial Officer6.3yrsUS$2.61m0%
$ 0
Thomas Smith
Executive VP & Chief Medical Officer2.7yrsUS$2.04m0%
$ 0
Vikram Karnani
CEO, President & Directorno datapas de donnéespas de données
Christopher James
Vice President of Investor Relationsno datapas de donnéespas de données
Bart Dunn
Executive Vice President of Strategy & Corporate Development5.2yrspas de donnéespas de données
Scott Sudduth
Head of Technical Operations3.1yrspas de donnéespas de données

4.3yrs

Durée moyenne de l'emploi

50.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de COLL est considérée comme expérimentée (ancienneté moyenne 4.3 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Michael Heffernan
Co-Founder & Chairman21.1yrsUS$330.61k0.087%
$ 840.7k
Vikram Karnani
CEO, President & Directorno datapas de donnéespas de données
John Freund
Independent Director10.8yrsUS$298.61k0.22%
$ 2.1m
Garen Bohlin
Independent Director9.8yrsUS$299.61k0.0073%
$ 70.6k
Gino Santini
Lead Independent Director12.3yrsUS$322.61k0.079%
$ 763.3k
Bill McCarberg
Scientific Advisorno datapas de donnéespas de données
Robert Dworkin
Scientific Advisorno datapas de donnéespas de données
Lynn Webster
Scientific Advisorno datapas de donnéespas de données
John Fallon
Independent Director8.4yrsUS$289.61k0.12%
$ 1.1m
Cynthia McCormick
Scientific Advisorno datapas de donnéespas de données
Richard Rauck
Scientific Advisorno datapas de donnéespas de données
Charles Argoff
Scientific Advisorno datapas de donnéespas de données

10.3yrs

Durée moyenne de l'emploi

68.5yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la COLL est chevronné et expérimenté ( 10.3 années d'ancienneté moyenne).